Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9039 results

  1. VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]

    Awaiting development Reference number: GID-TA12478 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423]

    Awaiting development Reference number: GID-TA12474 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]

    Awaiting development Reference number: GID-TA12469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 years

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  10. Single-incision short sling mesh insertion for stress urinary incontinence in women

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]

    In development Reference number: GID-TA11996 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  12. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  13. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    In development Reference number: GID-TA11625 Expected publication date:  16 December 2026

    Technology appraisal guidance
    In development